A Phase 1 Study of JNJ-79635322 in People With Multiple Myeloma or AL Amyloidosis


Full Title

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis


Researchers want to find the best dose of JNJ-79635322 to use in people with multiple myeloma or AL amyloidosis. The people in this study have multiple myeloma or AL amyloidosis that keeps growing even after treatment. Multiple myeloma is a cancer of the bone marrow. AL amyloidosis happens when a protein called amyloid builds up in organs and prevents them from working properly.

JNJ-79635322 binds to proteins on cancer cells and immune cells (T cells). This binding action may strengthen your immune system’s ability to fight cancer cells and destroy your tumor. JNJ-79635322 is given as a subcutaneous (under the skin) injection.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have multiple myeloma or AL amyloidosis that came back or keeps growing even with treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Saad Usmani’s office at 646-608-4165.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID